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Abstract
Background:  Germline mutations in the tumor suppressor PTEN predispose human beings to
breast cancer, and genetic and epigenetic alterations of PTEN are also detected in sporadic human
breast cancer. Germline Pten mutations in mice lead to the development of a variety of tumors, but
mammary carcinomas are infrequently found, especially in mice under the age of six months.
Results:  To better understand the role of PTEN in breast tumor development, we have crossed
Pten heterozygous mice to MMTV-Wnt-1 transgenic mice that routinely develop ductal carcinomas
in the mammary gland. Female Wnt-1 transgenics heterozygous for Pten  developed mammary
tumors earlier than Wnt-1 transgenics that were wild type for Pten. In most tumors arising in Pten
heterozygotes, the Pten wild-type allele was lost, suggesting that cells lacking Pten function have a
growth advantage over cells retaining a wild type allele. Tumors with LOH contained high levels of
activated AKT/PKB, a downstream target of the PTEN/PI3K pathway.
Conclusions:  An animal model has been developed in which the absence of Pten collaborates with
Wnt-1 to induce ductal carcinoma in the mammary gland. This animal model may be useful for
testing therapies specific for tumors deregulated in the PTEN/PI3K/AKT pathway.
Introduction
Cancer evolves from the accumulation of mutations and
the deregulation of two classes of genes, oncogenes and
tumor suppressor genes. The large majority of breast
cancers arise in epithelia of the breast, and they are
thought to evolve from hyperplasia with atypia to carci-
noma in situ, invasive carcinoma, and, finally, metastatic
disease. The molecular mechanisms leading to breast
malignancies are unclear, but many genetic abnormali-
ties and epigenetic factors have been implicated, includ-
ing changes affecting known tumor suppressor genes
(p53, BRCA1, BRCA2, PTEN/MMAC1/TEP1) and proto-
oncogenes (neu/ErbB2/HER2, ErbB1/EGFR, PRAD-1/
cyclin D1, Mdm2, and c-myc) [reviewed in ref. 1].
The gene product of PTEN (phosphatase and tensin ho-
molog deleted from chromosome 10) is a lipid phos-
phatase that reverses the activities of
phosphatidylinositol 3-kinase (PI3K) by dephosphor-
ylating the D3 position of its lipid products, phosphati-
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dylinositol-3, 4 bis-phosphate (PtdIns(3,4)P2),
phosphatidylinositol-3,5 bis-phosphate (PtdIns(3,5)P2),
and 3,4,5-tri-phosphate (PtdIns(3,4,5)P3) [2, 3], the ele-
vated levels of which are linked to the transforming abil-
ity of PI3K [reviewed in ref. 4].
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 recruit AKT (also
known as protein kinase B [PKB]) to the membrane
through the N-terminal pleckstrin homology (PH) do-
main of AKT [reviewed in ref. 5]. Membrane localization
renders AKT permissive to phosphorylation by phos-
phatidyl inositol-dependent kinases, PDK1 and PDK2, at
Thr308 within the activation loop and at Ser473 near the
carboxyl terminus. Phosphorylation activates the kinase
domain of AKT, which, in turn, phosphorylates target
proteins on serine and threonine residues. Substrates of
AKT include glycogen synthase kinase 3 (GSK3), p70/S6
kinase, BAD, Caspase 9, 4E-BP1, Iκ B kinase α  and mem-
bers of the Forkhead transcription family [reviewed in
ref. 6, 7]. Constitutive membrane localization of AKT
leads to its deregulated activation and can induce onco-
genic transformation [8, 9].
All three human members of the AKT family are over-
produced in various human cancers. AKT1 is over-ex-
pressed in gastric adenocarcinomas and breast cancer
cell lines, AKT2 is amplified and over-expressed in pan-
creatic, ovarian, and breast cancers, and AKT3 is upreg-
ulated in estrogen receptor-deficient breast cancer and
in androgen-independent prostate cell lines [reviewed in
ref. 6].
Consistent with the role of PTEN as a lipid phosphatase,
PTEN-deficient human and mouse cells have elevated
levels of intracellular PtdIns(3,4,5)P3 [10, 11] and dem-
onstrate constitutive activation of AKT in the absence of
growth factors [12,13,14]. The relationship between com-
ponents of this pathway is also conserved in flies and
worms.
A germline mutation in PTEN is associated with multi-
neoplastic, autosomally dominant syndromes in hu-
mans, such as Cowden disease and Bannayan-Zonana
syndrome (also known as Bannayan-Riley-Ruvalcaba
syndrome), and 20-50% of affected females in these fam-
ilies develop breast cancer [15,16,17]. The PTEN gene is
also frequently deleted or mutated in a variety of sporad-
ic human malignancies, such as glioblastoma and carci-
nomas of the prostate, endometrium and breast.
Although somatic mutations in the gene have been de-
tected in only about 1% of breast cancers, loss of hetero-
zygosity (LOH) at the PTEN locus (10q23) is frequently
found (approximately 40%), and 33% of breast tumors
have no detectable, or reduced, levels of the protein
product [18,19,20,21,22].
Three independent mouse lines carrying inactivating
Pten mutations have been made [23,24,25]. All mice ho-
mozygous for these Pten mutations die during early em-
bryogenesis. By 6 months of age, heterozygous mice
develop tumors of the lymphoid system, colon, uterus,
and adrenal medulla with very high penetrance, and tu-
mors of the prostate and thyroid with lower penetrance.
While benign mammary lesions, usually fibroadenomas,
are found in female mice after 7 months of age, few ani-
mals develop ductal carcinomas [KP and RP, unpub-
lished; 26], which account for over 85% of human breast
cancers.
In an effort to develop a model for studying the effects of
Pten inactivation in mammary oncogenesis, we have in-
troduced an additional genetic alteration, an MMTV-
Wnt-1 transgene, by breeding Pten heterozygotes [25]
with MMTV-Wnt-1 transgenic (TG) mice [27]. Female
mice harboring the Wnt-1 transgene develop extensive
mammary hyperplasia early in life, and 50% of them de-
velop mammary ductal carcinomas by 6 months of age
[27]. This transgene has been shown to collaborate with
Fgf-3 and inactivation of p53 to accelerate the appear-
ance of mammary tumors [28, 30]. After a mutant allele
of Pten was crossed into Wnt-1 TG mice, we found that
ductal carcinomas appeared earlier than either altera-
tion alone and that LOH at the Pten locus occurred in the
majority of these tumors, suggesting a selective growth
advantage in cells that lack Pten functions.
Results
Wnt-1 TG mice have been used to assess the functions of
a number of genetic lesions in breast carcinogenesis be-
cause tumors appear with predictable kinetics. The me-
dian age at which tumors are detected is 5-6 months in
MMTV-Wnt-1 TG females [27, 28, 30, 31]. After one mu-
tated allele of Pten was bred into this transgenic line, tu-
mors appeared significantly earlier than in sibling
females harboring only a MMTV-Wnt-1 transgene (P <
0.001, Fig. 1A). Fifty percent of Pten+/-, Wnt-1 TG fe-
male mice formed tumors by 3.5 months, 2.5 months
earlier than Wnt-1 TG mice (Fig. 1A). While it took one
year for the entire cohort (15) of Wnt-1 TG females with
a wild type Pten background to develop tumors, all Wnt-
1 TG, Pten+/- females showed tumors by 5 months of
age. Five each of Pten+/- mice without a Wnt-1 trans-
gene were monitored for 7 months and 10.5 months, but
none developed any palpable mammary lesions. These
observations differ from a recent report that one of the
other two Pten+/- lines develops fibroadenomas and ad-
enocarcinomas in the mammary tissue after 7 months of
age [26]. The lack of a mammary phenotype in our stud-
ies could be due to differences in the targeting con-
structs, the genetic backgrounds, or even environmental
agents.BMC Molecular Biology (2001) 2:2 http://www.biomedcentral.com/1471-2199/2/2
Figure 1
Pten heterozygosity accelerates tumor appearance in Wnt-1 TG females (A) and males (B). Percentages of mice that were
tumor-free, as determined by weekly visual inspection and/or palpation, were plotted against the age when tumors were found.
Genotypes and sizes are as indicated. For the Pten+/- female group without the Wnt-1 transgene, 10 mice were monitored to
30 weeks of age; among the 10 mice, 5 were kept for another 15 weeks of age. (A) All mice showed at least one adenocarci-
noma. (B) The Wnt-1 TG, Pten+/+ cohort (13) had 1 mammary and 3 salivary tumors, and the Wnt-1 TG, Pten+/- cohort (22)
had 2 mammary, 6 muzzle, and 14 salivary tumors.
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By one year of age, approximately 15% of Wnt-1 TG
males have been reported to develop mammary tumors
[27, 28, 31]. In our cross, one of the four tumors from
Wnt-1 TG males, in an otherwise wild type background,
was a mammary carcinoma; the other three tumors were
salivary in origin, with a similar histopathology to the
mammary lesion. The appearance of tumors was greatly
accelerated in the Pten heterozygous background (Fig.
1B). Fifty percent of males developed tumors by 5.5
months of age, and all developed tumors within 10
months. As in the case of Wnt-1 TG male mice without
Pten mutations, the majority of tumors (14/22) arose in
the salivary tissue; only a small number of tumors (2/22)
were mammary in origin, and, interestingly, some (6/22)
were bilateral or unilateral muzzle tumors of epithelial
origin, similar histopathologically to lesions found in
mammary and salivary tissues.
To determine if the wild type allele of Pten was inactivat-
ed in tumors arising in a Pten+/- background, 11 tumors
from Wnt-1 TG, Pten+/- mice were examined for LOH by
Southern hybridization. Seven tumors had lost the wild
type Pten allele (see Fig. 2 for an example of the analy-
sis). This result suggests that, in tumorigenesis, cells that
lack a functional allele of Pten have a significant prolifer-
ative advantage over the cells that retain the normal copy
of Pten.
Histological examination showed that tumors from Wnt-
1 TG mice, regardless of Pten status, were adenocarcino-
mas with cribriform, cystic and focal papillary growth
patterns. However, 3 of the 6 tumors that were Wnt-1
TG, Pten +/- with LOH appeared to have a higher nucle-
ar grade, more cellular stroma and a more infiltrative
pattern compared to the tumors without a Pten defect
(Fig. 3), suggesting a more aggressive phenotype.
In human cancer, a tumor suppressor gene can be inac-
tivated by mutations, chromosomal loss, promoter si-
lencing, and other means. To determine if the Pten
protein was produced in Wnt-1 TG, Pten+/- tumors that
did not undergo LOH, sections were analyzed using an
immunohistochemical assay with a polyclonal rabbit an-
tibody. Abundant amounts of Pten were detected in
mammary ducts from wild type mice. Pten was detected,
at reduced levels, in both hyperplastic ducts and mam-
mary tumors that did not have LOH at the Pten allele
(Fig. 4), suggesting that Pten was, indeed, made from the
second allele. Similar low levels of Pten were also detect-
ed in mammary ductal epithelial cells in Pten hetero-
zygous mice that did not have a Wnt-1 transgene,
suggesting that the Wnt-1 transgene does not influence
Pten expression. As expected, Pten was not detected in
tumors that had undergone LOH at the Pten locus (Fig.
4E).
Inactivation of Pten promotes membrane recruitment of
AKT and its subsequent activation by phosphorylation at
Ser473 and Thr308 [10, 11, 13]. All three human isoforms
of AKT have been found to be deregulated in human
breast cancer cells [32,33,34]. To determine if activated
AKT was increased in tumors that had a Pten defect,
these sections were stained using an antibody that spe-
cifically detects AKT1 phosphorylated at Ser 473 (and
AKT2 and AKT3 phosphorylated at equivalent sites). Tu-
mors that were Wnt-1 TG, Pten+/- with LOH displayed
staining of phosphorylated AKT (Fig. 5A). Surprisingly,
the staining was patchy, suggesting additional factors
may be required for AKT activation. As expected, phos-
phorylated AKT was undetectable in hyperplastic ducts,
in tumors from Wnt-1 TG, Pten+/+ mice, and tumors
from Wnt-1 TG, Pten+/- mice that retained the wild type
allele (Fig. 5B & 5C).
Several apoptotic pathways may be inhibited upon acti-
vation of AKT, promoting maintenance and survival of
tumor cells. Cellular proliferation may also be enhanced
by activated AKT, which inhibits p27 and GSK-3 (leading
to stabilization of cyclin D1) [35]. However, tumors from
Wnt-1 TG, Pten+/+ mice have low apoptotic rates (40 ±
16 per digital camera field using a 20x objective) and
high proliferation rates (53% ±  11). Neither apoptotic nor
proliferation rates were affected by the status of Pten
when measured by the TUNEL (terminal deoxynucleoti-
dyltransferase-mediated UTP end labeling) assay, which
labels the ends of fragmented DNA present in apoptotic
cells, and immunohistochemical staining for Ki67, a cell
proliferation marker (data not shown).
Most Wnt-1 TG mice (38/49) developed only one palpa-
ble tumor regardless of Pten status. Fifty-three of 55 sin-
gle sections from Pten+/+ glands that were free of a
Figure 2
Example  of  LOH  analysis.  Blots  of  tumor  and  tail  DNAs,
digested  with  PstI,  were  probed  with  a  32P  labeled  Pten
probe. Two bands could be observed, representing wild type
and mutant alleles, as indicated at the left. Genotypes of mice
are shown at the top.
+/-       +/-     +/-    +/-    +/+   +/+    +/-             
                            Tumors                    Tail
Mutant
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palpable mass did not show any lesions more advanced
than ductal hyperplasia. However, at the time of sacri-
fice, the majority (50/56) of glands from Wnt-1 TG,
Pten+/- mice had intra-ductal squamous lesions of vari-
ous sizes (Fig. 3D). These squamous lesions were usually
multi-focal and located both at the periphery of the ade-
nocarcinomas and in other mammary glands free of ade-
nocarcinomas.
Since Pten mutations are usually found in advanced tu-
mors, and the protein has been suggested to inhibit cell
spreading, migration, and invasion [36, 37], it is possible
that the tumors from Wnt-1 TG, Pten+/- mice may have
a higher potential to metastasize than those from mice
carrying a Wnt-1 transgene in a wild type Pten back-
ground. Wnt-1 TG mice occasionally show lymphoid or
pulmonary metastasis [27], and serial sectioning of lung
tissues from the animals reported here revealed microso-
copic metastatic foci in two of five lungs from Wnt-1 TG
mice bearing primary tumors 1.5-2.0 cm in size. Howev-
er, Wnt-1 TG mice and the Wnt-1 TG, Pten+/- mice har-
bored metastatic foci at similar frequencies (5/10).
(Statistical evaluation was not performed because the
sample sizes were too small.)
Discussion
Mouse models are valuable research tools for the study of
the molecular mechanisms of oncogenesis and for the
testing and screening of cancer therapeutic agents tar-
geted to specific oncogenic lesions. In order to produce
such a model for studying the effects of Pten mutations
in breast cancer, we have crossed Wnt-1 TG mice to mice
heterozygous for Pten. Mice transgenic for MMTV-Wnt-
1 and heterozygous for Pten developed mammary aden-
Figure 3
Representative H+E sections of mammary tumors from progeny females of the MMTV-Wnt-1 and Pten+/- cross. Sections were
from tumors that were Wnt-1 TG+, Pten+/+ (A); Wnt-1 TG+, Pten+/- (B); and Wnt-1 TG+, Pten+/- with LOH (C and D). A 40x
objective was used. Blue arrows indicate the smooth boundaries of tumors, red arrow marks the infiltrating front of the tumor,
and white arrows label the highly cellular stroma. (D) shows a part of an intraductal squamous lesion.BMC Molecular Biology (2001) 2:2 http://www.biomedcentral.com/1471-2199/2/2
ocarcinomas much earlier than mice carrying either le-
sion alone. The majority of tumors in Wnt-1 TG, Pten+/-
mice had lost the wild type allele of Pten, suggesting that
the complete inactivation of Pten function provides an
additional growth advantage to these tumors. LOH at the
Pten locus has recently been reported in mammary tu-
mors arising in Pten heterozygous mice [26], but only 4%
of the mice developed tumors before the age of 30 weeks,
and, in our cross, none of the Pten+/- mice without the
Wnt-1 transgene had a palpable mammary tumor before
the age of 30 weeks. LOH at the Pten locus has also been
reported in adrenal and lymphatic tumors, but not in
uterine tumors and prostate lesions in Pten+/- mice [KP
& RP, submitted; 38].
Activated AKT was more abundant in tumors that were
Wnt-1 TG, Pten +/- with LOH, as has been shown for
uterine tumors in Pten heterozygous mice (KP, RP, sub-
mitted). The presence of areas unstained with antibody
specific for phosphorylated AKT suggests that additional
factors other than Pten may influence the activation of
AKT.
Neither apoptosis nor proliferation, as determined by
the TUNEL assay and KI67 staining, was significantly
different between tumors heterozygous for Pten (with or
without LOH) and those without a Pten defect. This re-
sult may seem paradoxical since increased phosphorylat-
ed AKT, due to inactivation of Pten, suppresses apoptosis
and promotes proliferation. However, tumors in Wnt-1
TG mice in a wild type Pten background already have
Figure 4
Immunohistochemical staining for Pten. Sections of mammary glands (A, D) and tumors (B, C, E, F) were stained for Pten (A, B,
D, E, F) or control rabbit Ig (C) and counterstained with hematoxylin. Genotypes of mice were Pten+/+ (A); Wnt-1 TG, Pten+/
+ (B); and Wnt-1 TG, Pten+/- (C-F). (E) and (C, F) were from tumors with or without LOH, respectively. A 40x objective was
used.BMC Molecular Biology (2001) 2:2 http://www.biomedcentral.com/1471-2199/2/2
highly suppressed apoptosis and accelerated prolifera-
tion rates, and any incremental changes, if present, may
be difficult to detect with our current assays. Nonethe-
less, a seemingly minor difference in either apoptosis or
proliferation could have a dramatic impact on tumor
growth over time.
Accelerated appearance of mammary adenocarcinomas
in the presence of a Pten mutation suggests a synergy be-
tween Pten inactivation and the Wnt-1 transgene. The
apparent cooperation of these two genetic factors is fur-
ther strengthened by our finding that the majority of tu-
mors arising in a Pten+/- background have lost the wild
type allele. To date, heterozygous inactivation of any of
the other tumor suppressor genes implicated in breast
cancer, including P53, Brca1, Brca2, and Rb, has failed
to cooperate with Wnt-1 in promoting the appearance of
mammary tumors [reviewed in ref. 39]. Therefore, it is
possible that the signal pathway controlled by Pten is one
of the preferred partners of the Wnt-1 pathway in cancer
progression, although it remains possible that LOH at
the Pten locus is more likely to occur than for the other
alleles crossed into Wnt-1 TG mice. Even though Wnt-1
has not been directly implicated in human cancers, many
components of the Wnt signaling pathway (such as β -
catenin, APC, c-myc, and cyclin D1) are involved in hu-
man tumors including breast cancer [reviewed in ref.
40].
One of the goals of mouse modeling efforts is to provide
an opportunity for pre-clinical testing of generalized or
mechanism-specific therapeutics in a defined genetic
setting. Many human breast tumors have reduced levels
of PTEN, hence inhibitors of the cell signaling pathways
affected by PTEN could be tested in the model we have
developed. One such candidate is the rapamycin analog
Figure 5
Immunohistochemical staining for phosphorylated Akt. Sections of tumors were stained for phospho-Akt (A, B, C) or control
rabbit IgG (D) and counterstained with hematoxylin. Genotypes of mice were Wnt-1 TG+, Pten+/- (A, B); Wnt-1 TG+, Pten+/+
(C, D). (A) and (B) were from tumors with or without LOH, respectively. A 40x objective was used.BMC Molecular Biology (2001) 2:2 http://www.biomedcentral.com/1471-2199/2/2
CCI779, which has been suggested to inhibit the AKT sig-
naling pathway, probably through inhibition of mTOR
(target of rapamycin), a potential target of AKT [re-
viewed in ref. 41]. CCI779 has been shown to have inhib-
itory effects on the growth of Pten-deficient tumors in
the uterus and prostate in mice (KP & RP, submitted; M.
Neshat & C. Sawyers, submitted). Since tumors arise rap-
idly after a copy of Pten is inactivated, and with predict-
able kinetics, this model may be useful for testing the
efficacy of these therapies.
Results presented here and published earlier
[15,16,17,18, 26] have clearly demonstrated the signifi-
cant impact of Pten on mammary oncogenesis. Future
testing will examine the tumorigenic effects caused by
other kinds of genetic damage in the signaling pathways
affected by Pten. The TVA-directed gene delivery system
[reviewed in ref. 42] can be used to introduce viral vec-
tors carrying genes encoding an activated form of PI3K,
AKT, or candidate substrates for AKT into the mammary
tissue of Wnt-1 TG mice. This would allow the testing of
therapeutic interventions directed to specific steps of the
signaling pathway regulated by Pten.
Materials and methods
Mice
MMTV-Wnt-1 TG mice [27] and those that carry a mu-
tant allele of Pten [25] have been described. Male Wnt-1
TG mice (a mixture of FVB, SJL, and C57BL/6) were
crossed with Pten heterozygous females (a mixture of
C57BL/6 and 129SvJ) to generate all three genotypes
used in this paper: Wnt-1 TG, Pten+/-; Wnt-1 TG, Pten
+/+; and Pten+/-. Genotyping for the Wnt-1 transgene
was done using PCR as described [27]; PCR using prim-
ers from the neo cassette was performed to detect the
Pten knockout allele. Mice were monitored weekly for tu-
mor formation by visual inspection and/or palpation;
most tumors were found when they were approximately
0.5 cm. Most of tumors were harvested for further anal-
ysis when they were 1.5 cm in diameter. Tissues were
fixed in 10% buffered formalin and paraffin-embedded.
For histological survey, one H-E section per block was
analyzed.
Immunohistochemical staining and TUNEL assay
Formalin-fixed and paraffin-embedded sections were
deparaffined and rehydrated in several changes of xy-
lene, ethanol, and water. Antigen-unmasking was
achieved by boiling the slides for 15 minutes in citrate
buffer, pH 6.0, or 1 mM EDTA. Endogenous peroxidase
activity was inactivated by a 5 minute incubation in 3%
hydrogen peroxide, when needed. Immunohistochemi-
cal stainings were performed using Vector ABC kits (Vec-
tor Laboratories) following the manufacturer's
recommendations and as described [25]. Rabbit anti-
bodies against Pten, Ki67, and AKT phosphorylated at
Ser 473 were from Neomarkers, Dako, and New England
BioLabs, respectively. The TUNEL assay was performed
as described [25].
Southern hybridization
DNAs extracted from tissues and tumors were digested
with PstI, followed by electrophoresis, and blotted to Ny-
lon+ membrane. Hybridization was done in ExpressHyb
solution (Clontech) at 60° C using a 32P dCTP-labeled
probe that was synthesized from a 0.9 Kb template locat-
ed in intron 5 of Pten [25] using the RTS RadPrime DNA
labeling system (Life Technologies). The probe was incu-
bated with Cot-1 DNA (Life Technologies) at 70° C for 10
minutes before addition to the hybridization solution.
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